Back to Browse Journals » Vascular Health and Risk Management » Volume 5

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man

Authors Alessandra Del Fiorentino, Silvana Cianchetti, Alessandro Celi, Giulia Dell’Omo, Roberto Pedrinelli

Published Date February 2009 Volume 2009:5 Pages 233—242

DOI http://dx.doi.org/10.2147/VHRM.S4800

Published 8 February 2009

Alessandra Del Fiorentino, Silvana Cianchetti, Alessandro Celi, Giulia Dell’Omo, Roberto Pedrinelli

Dipartimento Cardio Toracico e Vascolare, Università di Pisa, Italy

Abstract: Anti-inflammatory properties may contribute to the pharmacological effects of angiotensin II receptor blockers (ARBs), a leading therapeutic class in the management of hypertension and related cardiovascular and renal diseases. That possibility, supported by consistent evidence from in-vitro and animal studies showing pro-inflammatory properties of angiotensin II, has been evaluated clinically by measuring the effect of ARBs on C-reactive protein and other circulating indices of inflammation (e-selectin, adhesion molecules, interleukin-6, tissue necrosis factor-alpha, monocyte chemoattractant protein-1) of potential clinical relevance, a body of evidence that this paper aims to review.

Keywords: renin–angiotensin system, angiotensin II type 1 receptor blockers, vascular inflammation, C-reactive protein, circulating inflammatory markers

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Lack of a relationship between circulating gamma-glutamyltransferase levels and carotid intima media thickness in hypertensive and diabetic patients

Nuti M, Spontoni P, Grigoratos C, Dell'Omo G, Balbarini A, Pedrinelli R

Vascular Health and Risk Management 2012, 8:275-281

Published Date: 1 May 2012

Readers of this article also read:

Absorbable stent: focus on clinical applications and benefits

Gonzalo N, Macaya C

Vascular Health and Risk Management 2012, 8:125-132

Published Date: 29 February 2012

Treatment of pediatric pulmonary hypertension

Amy Hawkins, Robert Tulloh

Vascular Health and Risk Management 2009, 5:509-524

Published Date: 3 June 2009

Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials

Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia

Vascular Health and Risk Management 2009, 5:411-427

Published Date: 8 May 2009

Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension

Amber Lundy, Nahla Lutfi, Cherylyn Beckey

Vascular Health and Risk Management 2009, 5:429-440

Published Date: 8 May 2009

Arterial stiffness in insulin resistance: The role of nitric oxide and angiotensin II receptors

Divina G Brillante, Anthony J O’Sullivan, Laurence G Howes

Vascular Health and Risk Management 2009, 5:73-78

Published Date: 4 December 2008

Cardiovascular co-morbidity in rheumatic diseases

Carl Turesson, Lennart TH Jacobsson, Eric L Matteson

Vascular Health and Risk Management 2008, 4:605-614

Published Date: 29 July 2008

Antiplatelet drugs in cardiological practice: Established strategies and new developments

Florian Krötz, Hae-Young Sohn, Volker Klauss

Vascular Health and Risk Management 2008, 4:637-645

Published Date: 30 June 2008

Trandolapril/verapamil combination in hypertensive diabetic patients

José A García Donaire, Luis M Ruilope

Vascular Health and Risk Management 2007, 3:77-82

Published Date: 18 May 2007

Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes

Joseph Colin

Clinical Ophthalmology 2007, 1:441-453

Published Date: 10 January 2007